Burstein HJ et al. Clinical activity of trastuzumab and vinorelbine in women withHER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19(10):2722-30. Abstract

Paik S et al. Real world performance of HER2 testing – National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 2002;94:852-4. Abstract

Paik S et al. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin. Breast Cancer Res Treat 2002;76(Suppl 1);Abstract 9.

Perez EA et al. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: A North Central Cancer Treatment Group randomized phase II trial. Breast Cancer Res Treat 2003;Abstract 216.

Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9. Abstract

Press MF et al. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20(14):3095-105. Abstract

Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 35.

Roche PC et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002;94:855-7. Abstract

Seidman AD et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587-95. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract

Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract